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HER2-positive breast cancer accounts for 20–30% of all breast cancers and has the second-
poorest prognosis among breast cancer subtypes.The approval of trastuzumab in 1998 has
significantly improved patients’ outcomes and paved the way for the beginning of advent of
targeted approaches in breast cancer treatment. However, primary or acquired resistance
to trastuzumab has been increasingly recognized as a major obstacle in the clinical man-
agement of this disease. In addition, in clinical practice, there are currently no conclusive
biomarkers for patient response to trastuzumab. Therefore, understanding the molecular
mechanism of trastuzumab and the development of resistance to this drug are of interest.
Such understanding will provide the guidance critically needed for the design of better com-
bination therapy and will allow the appropriate selection of patients who are responsive
to trastuzumab-based strategies. In line with that, our review highlights the well-accepted
mechanisms of action and resistance to the therapy and discusses the progress that has
been made toward successfully overcoming this resistance.
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INTRODUCTION
The family of epidermal growth factor receptors comprises HER1,
HER2, HER3, and HER4. These tyrosine kinases play a critical
role in cellular growth and are frequently up-regulated in numer-
ous cancers, including breast carcinoma (Browne et al., 2009). The
overexpression or gene amplification of HER2 has been found in
about 20–30% of breast cancers, which is classified as the HER2-
positive subtype (Slamon et al., 1987; Seshadri et al., 1993; Owens
et al., 2004). HER2-positive breast cancer has the second-poorest
prognosis among breast cancer subtypes and is correlated with
lower disease-free and overall survival rates (Slamon et al., 1987;
Tandon et al., 1989; Seshadri et al., 1993; Andrulis et al., 1998; Paik
et al., 2000). Typically, HER2 is expressed at a low level on the
surface of epithelial cells and is necessary for the normal develop-
ment of many tissues, including those of the breast, ovary, lung,
liver, kidney, and central nervous system (Browne et al., 2009).
In contrast, in breast cancer cells, immunohistochemical analyses
have revealed extremely high levels of HER2, which can reach up
to two million receptors per cell (Slamon et al., 1987; Browne et al.,
2009). The overexpression of HER2 is of crucial importance since
its activation triggers multiple downstream pathways required for
the abnormal proliferation of cancer cells (Browne et al., 2009).
Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; Akt, protein
kinase B; c-Cbl, Casitas B-lineage lymphoma; CDK2, cyclin-dependent kinase 2;
EGFR, epidermal growth factor receptor; EpoR, erythropoietin receptor; HGF, hepa-
tocyte growth factor; IGFBP3, IGF-binding protein-3; IGFR, insulin-like growth
factor receptor; MAPK, mitogen-activated protein kinase; PI3K, phosphatidyli-
nositol triphosphate kinase; PTEN, phosphatase and tensin homolog; rHuEPO,
recombinant human erythropoietin.
HER2 is activated by the formation of homodimers or het-
erodimers with other EGFR proteins. This dimerization results
in autophosphorylation and/or transphosphorylation of specific
tyrosine residues in EGFR intracellular domains, which in turn
leads to the activation of the Ras/Raf/mitogen-activated protein
kinase, the phosphoinositide 3-kinase/Akt, and the phospholi-
pase Cγ (PLCγ)/protein kinase C (PKC) pathways (Browne et al.,
2009). Of note, the HER2-HER3 heterodimer is the most potent
stimulator of downstream pathways, particularly the PI3K/Akt,
a master regulator of cell growth and survival (Alimandi et al.,
1995; Lee-Hoeflich et al., 2008). Moreover, HER2 dimerization
promotes the mislocalization and rapid degradation of cell cycle
inhibitor p27Kip1 protein leading to cell cycle progression. Some
of the well studied pathways affected by activation of HER2 are
briefly described in Figure 1.
MECHANISMS OF ACTION OF TRASTUZUMAB
Given that HER2 is frequently up-regulated in breast cancer and
is correlated with poor prognosis, targeting HER2 is an attrac-
tive therapeutic approach. The first Food and Drug Adminis-
tration (FDA)-approved targeted therapy for breast cancer was
trastuzumab (Gajria and Chandarlapaty, 2011). Trastuzumab (or
Herceptin) was developed by Genentech Inc (San Francisco, CA,
USA) as a recombinant humanized monoclonal antibody directed
against the extracellular domain IV of HER2 (Carter et al., 1992),
has served as a remarkable example of a successful targeted ther-
apy in breast cancer. Clinical studies have shown that the com-
bination of trastuzumab with standard chemotherapy produces
far better response rates than does chemotherapy alone (Sla-
mon et al., 2001; Vogel et al., 2002). Thus, the combinations that
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FIGURE 1 | HER2 signaling pathway. Receptor homodimerization or
heterodimerization is the prerequisite step for HER2 activation. Its activation
then triggers a broad spectrum of downstream cascades to promote
numerous effects, including cell growth, proliferation, and survival. PI3K/Akt is
one of the most well studied pathways activated by HER2. Activated PI3K/Akt
also triggers mTOR, a master positive regulator of cell metabolism. In
addition, HER2 activation can activate Ras/Raf and MEK pathways, which
favors cancer cells’ growth and migration.
include trastuzumab have been considered as the standard of care
for HER2-overexpressing breast cancer patients (Hudis, 2007).
In this part, we focus on the molecular mechanisms of actions
of trastuzumab, which are grouped into three major categories,
summarized below.
HER2 DEGRADATION
Trastuzumab has been proposed to trigger HER2 internaliza-
tion and degradation through promoting the activity of tyrosine
kinase – ubiquitin ligase c-Cbl (Klapper et al., 2000). It was
observed that the binding of trastuzumab to HER2 recruits c-
Cbl to its docking site, Tyr1112 where c-Cbl ubiquitinates HER2
and leads to its degradation. However, how c-Cbl is induced
as trastuzumab binds to HER2 and how c-Cbl mediates HER2
degradation remain obscure.
ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
As an antibody, one of the major mechanisms of trastuzumab is
to attract immune cells to tumor sites that overexpress HER2,
by a mechanism called antibody-dependent cellular cytotoxic-
ity (ADCC). Xenografts study by Clynes et al. (2000) showed
that natural killer cells could target HER2-overexpressing cells
coated with trastuzumab via a CD16-mediated ADCC mechanism.
Arnould et al. (2006) later confirmed the immune cell-modulated
activity of trastuzumab by using samples from patients with locally
advanced breast cancer. After treating the tumor samples with
trastuzumab and docetaxel, the group observed an increase in the
number of both natural killer cells and cytotoxic proteins in tumor
infiltrates (Arnould et al., 2006). These findings provide strong
support for ADCC as a mechanism of action of trastuzumab and
help explain why cancer cells with high HER2 expression are more
responsive to the drug.
MAPK AND PI3K/Akt INTERFERENCE
The most well known effect of trastuzumab is the inhibition of
the MAPK and PI3K/Akt pathways (Figure 1), which leads to an
increase in cell cycle arrest, and the suppression of cell growth
and proliferation. It is widely accepted that by interfering with
the dimerization of HER2, trastuzumab inhibits HER2 activation
and suppresses Akt phosphorylation (Junttila et al., 2009). Other
groups critically showed that trastuzumab, by binding to HER2,
can block tyrosine kinase Src signaling and thus, increases PTEN
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FIGURE 2 | Resistant mechanism to trastuzumab. (1) Steric effects or
masking of the trastuzumab-binding sites. The truncated form of HER2
(p95HER2) that lacks trastuzumab-binding domain can no longer be
inhibited by trastuzumab. The remaining structure can still dimerize with
other receptors and therefore can still trigger downstream cascades. (2)
Alternative elevations of other receptor tyrosine kinases. The
overexpression of other growth factor receptors, such as c-Met and
IGF-1R, the two most commonly reported, can trigger similar effects on
cell behavior, even though HER2 signaling is inhibited by trastuzumab. (3)
Intracellular alterations. In trastuzumab resistant cells, PTEN function is
lost; thus, Akt is constitutively active. Also, resistant cells can harbor
activating mutations in PI3K or Akt, which can trigger other downstream
signaling pathways even when HER2 is blocked by trastuzumab or when
PTEN is active.
level and activity. This also results in the suppression of PI3K/Akt
signaling and reduction in cell growth and survival (Nagata et al.,
2004; Zhang et al., 2011). Moreover, trastuzumab was demon-
strated to induce cell cycle arrest by restoring p27 and suppressing
CDK2 activity in BT474 and SKBR3 breast cancer cells.
In general, trastuzumab, by binding to extracellular domain of
HER2, can potently suppress cancer cells growth, proliferation,
and survival in both direct and indirect manners.
MECHANISMS OF TRASTUZUMAB RESISTANCE
Even though trastuzumab has significantly improved outcome in
breast cancer patients and has paved the way for the era of tar-
geted therapy in breast cancer treatment, the median duration of
response is modest (Gajria and Chandarlapaty, 2011; Zhang et al.,
2011). This is due to either primary or secondary mechanisms of
resistance to the therapy. Less than 35% of patients with HER2-
positive breast cancer initially respond to trastuzumab (Wolff
et al., 2007; Narayan et al., 2009), which means these patients are
“primarily” or “inherently” resistant to the drug. On the other
hand, about 70% of patients who initially responded experi-
ence progression to metastatic disease within a year (Gajria and
Chandarlapaty, 2011), suggesting that “secondary” or “acquired”
resistance to trastuzumab frequently develops. Some tumor sup-
pressor proteins and oncoproteins, such as PTEN and Src, have
biological significance and play overlapping roles in both pri-
mary and acquired resistance (Nagata et al., 2004; Zhang et al.,
2011). On the other hand, little information on the basis of pri-
mary and secondary resistance is available (Narayan et al., 2009).
In this review, we classified the potential mechanisms of resis-
tance to trastuzumab according to the inter- or intra-networks
of HER2 signaling. These are summarized in three major cate-
gories, briefly described in Figure 2: (1) the steric effects, such
as the structural mutation in HER2 protein, (2) the alternative
elevations of other tyrosine kinase receptors, such as insulin-
like growth factor receptor (IGFR), or (3) the intracellular alter-
ations in HER2 downstream signaling, notably phosphatase and
tensin homolog (PTEN) deficiency and/or PI3K/Akt constitutive
active.
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STERIC EFFECTS
HER2 can mutate to “cut off” its extracellular domain, which
inhibits the binding of trastuzumab to the receptor (Scott et al.,
1993; Christianson et al., 1998). This process is called proteolysis,
which generates the truncated p95HER2 isoform with constitutive
kinase activity (Scott et al., 1993; Christianson et al., 1998; Scaltriti
et al., 2007). This mutated isoform promotes the continuous acti-
vation of oncogenic signaling and bypass trastuzumab’s effects.
In a study of tumor cells from 46 patients with metastatic breast
cancer, those who acquired the p95HER2 mutation were less likely
to respond to trastuzumab than were those with full-length HER2
(Scaltriti et al., 2007). However, how cancer cells can induce HER2
proteolysis in response to trastuzumab has not been examined.
Another mechanism that may contribute to the “masking” of the
trastuzumab-binding site on HER2 is the elevated expression of
mucin-4. Mucin-4, a highly O-glycosylated membrane protein, is
also the putative partner of HER2, and its expression was corre-
lated with poor prognosis in not only breast cancer but also other
carcinoma types (Nagy et al., 2005). However, how Mucin-4 is
overexpressed in trastuzumab resistant cells and by what mecha-
nism Mucin-4 confers resistance to the therapy required further
studies.
OVEREXPRESSION OF OTHER TYROSINE KINASE RECEPTORS
Since trastuzumab does not prevent HER3 dimerization
(Wehrman et al., 2006), the overexpression of HER3 could over-
come trastuzumab-mediated inhibition of HER2 signaling. It
was previously found that co-expression of HER3 and HER2 is
required for the transformation of NIH-3T3 cells (Alimandi et al.,
1995) and that HER2-HER3 dimerization results in increased tyro-
sine phosphorylation of HER3 which subsequently increases PI3K
recruitment and downstream activation (Alimandi et al., 1995;
Holbro et al., 2003). These findings imply that cancer cells, by uti-
lizing HER3 signaling, can compensate for the inhibition of HER2
signaling mediated by trastuzumab.
Another promising target whose aberrant expression may con-
fer resistance to trastuzumab is insulin-like growth factor 1 recep-
tor (IGF-1R). Lu et al. (2001) found that ectopic expression of
IGF-1R drives trastuzumab-sensitive SKBR3 cells to resistant to
the therapy. Also, IGF-1R-overexpressing SKBR3 cells show sig-
nificantly low levels of p27Kip1, p21Cip1 proteins, and a high level
of CDK2 kinase activity (Lu et al., 2001). This indicates that IGF-
1R-overexpressing cells, by overcoming cell cycle arrest mediated
by trastuzumab contribute to the drug resistance. Interestingly,
the resistance is reversed by suppression of IGF-1R signaling with
recombinant IGF-binding protein-3 (IGFBP3) or by gradual heat-
induced expression of the dominant-negative IGF-1R 486/STOP
(Lu et al., 2001; Jerome et al., 2006). This further confirms that
the elevation of IGF-1R significantly contributes to trastuzumab
resistance.
Notably, the overexpression of tyrosine kinase c-Met has
emerged as a potential contributor to trastuzumab. c-Met is a
critical oncogene that encodes for a receptor tyrosine kinase com-
posed of an α chain disulfide linked to a β subunit (Bottaro et al.,
1991). c-Met, until now, is reported to have only one known ligand
called hepatocyte growth factor (HGF) and is normally expressed
in epithelial and endothelial cells (Bottaro et al., 1991). Although
Met signaling is actively involved in the regeneration and devel-
opment of various organs, c-Met and HGF have been reported to
be overexpressed in human breast carcinomas and tumor stroma,
respectively. Moreover, c-Met overexpression is correlated with
poor prognosis in breast cancer patients (Kang et al., 2003). Fur-
thermore, c-Met was shown to be highly elevated in HER2-positive
breast cancer cell lines and in 25% of HER2-positive breast cancer
patients’ tissues (Yamashita et al., 1994; Lindemann et al., 2007;
Shattuck et al., 2008). More importantly, c-Met has recently been
demonstrated to physically interact with HER2 (Agarwal et al.,
2009). These findings suggest that c-Met synergizes with HER2
signaling to confer resistance to trastuzumab. Sweeney’s group,
indeed, revealed that depletion of c-Met makes the cells more sen-
sitive to trastuzumab and that trastuzumab rapidly up-regulates
c-Met expression in vitro (Shattuck et al., 2008). These findings
imply that c-Met overexpression is critical for treatment-acquired
resistance to trastuzumab. However, further studies are needed
to strengthen our knowledge of the contribution of c-Met to
trastuzumab resistance and to understand how c-Met is elevated
in resistant cells.
Moreover, Liang et al. (2010) found that recombinant human
erythropoietin (rHuEPO), which has long been used to manage
the anemia and fatigue caused by cancer treatment, antagonizes
trastuzumab’s effects on breast cancer models both in vitro and
in vivo. This group demonstrated that, in a panel of 10 pri-
mary breast cancer cell lines, 5 express the erythropoietin receptor
(EpoR), and 2 have relatively high levels of both HER2 and EpoR.
These observations indicate that EpoR and HER2 are overex-
pressed in the same cancer cells. Furthermore, using the same
cell lines, they found that rHuEPO significantly reduces the cell
growth inhibition induced by trastuzumab. rHuEPO also trig-
gers the PI3K/Akt and Src pathways, leading to the suppression of
PTEN and trastuzumab’s effects. This was confirmed by a mouse
xenografts study in which rHuEPO introduction promotes tumor
growth suppressed by trastuzumab (Liang et al., 2010). These ele-
gant models suggested that rHuEPO administration contributes
to the resistance to trastuzumab.
INTRACELLULAR ALTERATIONS
One of the most under-investigated “driving forces” involved in
trastuzumab resistance is PTEN. Nagata et al. (2004) reported
that the loss of PTEN was observed in 36% of HER2-positive
primary breast tumor specimens from patients with stage IV
disease. In addition, they also showed that patients with PTEN-
deficient tumors had remarkably lower overall response rates to
trastuzumab than did patients with wild-type PTEN. Later on,
other group reported 25% of PI3KCA activating mutation and
20–25% of PTEN deficiency in tumors from a cohort of 55
patients resistant to trastuzumab (Berns et al., 2007; Kataoka et al.,
2010). They found that trastuzumab-treated patients with activat-
ing PI3KCA mutations had significantly shorter progression-free
survival than did those without mutations. The group also demon-
strated that HER2-positive breast cancer cell lines with activating
PIK3CA mutations (E545K and H1047R) are more resistant to
trastuzumab than are HER2-positive cell lines without those muta-
tions (Berns et al., 2007; Kataoka et al., 2010). These studies suggest
that constitutive active PI3K/Akt pathway, either due to PTEN loss
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or activating mutations in PIK3CA, significantly contributes to
both inherent and acquired resistance to trastuzumab.
PTEN deficiency that may confer resistance to the therapy was
recently confirmed by Yu’s group (Zhang et al., 2011). Of inter-
est, the group also found that Src is activated in breast cancer
cell lines which is associated with both primary and acquired
resistance to trastuzumab. Specifically, they revealed that patients
with active Src were significantly less responsive to trastuzumab
than were those without Src activation. In terms of molecu-
lar networking, they showed that Src is the central mediator
of all resistant pathways. Those features enable Src a promising
“global” therapeutic target for patients resistant to trastuzumab.
Furthermore, Src inhibition can reverse trastuzumab resistance
in vitro and in vivo, specifically through effectively blocking Akt
phosphorylation and downstream signaling of EGFR, even in
PTEN-deficient cells. This poses a novel promising approach
of combining trastuzumab and Src inhibition for better clinical
benefit in a large population of patients with poor response to
trastuzumab.
CONCLUDING REMARKS
A number of critical studies have been conducted to identify
the mechanisms that account for trastuzumab’s effects and the
resistance to the therapy. Notably, multiple mechanisms may act
simultaneously to confer resistance to the drug, due to the accumu-
lation of intracellular alterations and the heterogeneity of breast
cancer. For this reason, it is clinically unfeasible to extensively
combine various therapeutic targets. Therefore, further studies
are urgently needed to distinguish “driving force” from “bypass”
mechanisms. This, together with the clarification of primary and
acquired resistance, will ultimately help in designing more specific
and effective combination therapies.
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